Transcription factors, translocations, and leukemia

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Transcription factor (TF) genes are frequently involved in chromosomal translocations associated with leukemia.
• The diverse TFs and cellular maturation stages implicated suggest multiple mechanisms beyond recombinase activity.
• Identifying TF gene translocations in solid tumors is challenging due to sample acquisition difficulties, but improving cytogenetic analysis and advanced techniques like FISH and PCR are aiding discovery.

Purpose of the Study:

• To explore the role of transcription factor gene abnormalities in various malignancies, including leukemia and solid tumors.
• To detail how chromosomal translocations in acute leukemia alter TF expression and activity.
• To discuss the potential for targeted therapies based on identified TF abnormalities.

Main Methods:

• Review of existing literature on TF gene involvement in leukemia and solid tumors.
• Analysis of how chromosomal translocations affect TF gene expression, RNA transcripts, and protein function.
• Discussion of advanced techniques like fluorescent in situ hybridization (FISH) and PCR for detecting genetic abnormalities.

Main Results:

• Chromosomal translocations in acute leukemia can generate fusion RNA transcripts and TF proteins with altered functions.
• Other translocations lead to aberrant gene expression, altered expression levels, or changes in promoter usage and exon structure.
• TF gene abnormalities, beyond translocations, are observed in nonhematopoietic malignancies, with p53 abnormalities being common in many solid tumors.

Conclusions:

• While the exact mechanisms of TF gene involvement in leukemia translocations are still under investigation, advanced techniques are facilitating their discovery in various cancers.
• Abnormal TFs resulting from these rearrangements may offer specific targets for novel therapeutic strategies.
• Targeted therapies, including antisense, ribozyme, and immunologic approaches, show promise for inhibiting cancer cell growth by targeting these molecular abnormalities.